Gary Matoren is leaving a lasting impact on students at Stony Brook University by dedicating his estate to support future research in preventing genetic disorders. Matoren, whose career spanned various healthcare sectors including pharmacy, administration, and clinical research, was driven by personal tragedy. His daughter, Debbie Lynn, was born with a heart defect linked to a medication prescribed for morning sickness.
“The pharmaceutical healthcare field remained my focus because of my youngest daughter Debbie Lynn,” Matoren explained. Motivated by his daughter's experience, Matoren contributed significantly to drug toxicity studies and disease etiology. He also edited "The Clinical Research Process in the Pharmaceutical Industry" and founded "Clinical Research Practices and Drug Regulatory Affairs."
Matoren has chosen to channel his resources into Stony Brook University's Renaissance School of Medicine through two fellowships and a scholarship. “I live a frugal lifestyle,” he shared, “and I want to give back to students to help them achieve their goals and further advance clinical research.”
Scott Barrett, interim vice president for University Advancement at Stony Brook, expressed gratitude for this contribution: “We are honored that Gary chose Stony Brook as the place for his remarkable philanthropic legacy. This extraordinary gift represents more than just a visionary commitment — it establishes a perpetual support for students and their research.”
Readers can find more details in Christine McGrath's full story at SB Matters.